These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17950157)

  • 1. A perspective on coronary revascularization in the PROactive 05 study.
    Riche DM; Dale KM
    J Am Coll Cardiol; 2007 Oct; 50(17):1705-6; author reply 1706. PubMed ID: 17950157
    [No Abstract]   [Full Text] [Related]  

  • 2. PROactive in patients with type 2 diabetes and previous myocardial infarction: swinging the sword of Damocles?
    Westerbacka J
    J Am Coll Cardiol; 2007 May; 49(17):1781-2. PubMed ID: 17466228
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PROactive study: some answers, many questions.
    Yki-Järvinen H
    Lancet; 2005 Oct; 366(9493):1241-2. PubMed ID: 16214581
    [No Abstract]   [Full Text] [Related]  

  • 5. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
    Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
    Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone and bladder cancer.
    Hillaire-Buys D; Faillie JL; Montastruc JL
    Lancet; 2011 Oct; 378(9802):1543-4; author reply 1544-5. PubMed ID: 22035550
    [No Abstract]   [Full Text] [Related]  

  • 8. Pioglitazone and bladder cancer.
    Ryder RE
    Lancet; 2011 Oct; 378(9802):1544; author reply 1544-5. PubMed ID: 22035551
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
    Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
    Circulation; 2014 Apr; 129(16):e460-1. PubMed ID: 24753557
    [No Abstract]   [Full Text] [Related]  

  • 11. [Insulin sensitizer improves lipid profile. Infarct prevention for type 2 diabetic patients?].
    MMW Fortschr Med; 2002 Dec; 144(50):67. PubMed ID: 14610877
    [No Abstract]   [Full Text] [Related]  

  • 12. PROactive study.
    Guillausseau PJ
    Lancet; 2006 Jan; 367(9504):23; author reply 26-7. PubMed ID: 16399140
    [No Abstract]   [Full Text] [Related]  

  • 13. PROactive Study: (r)evolution in the therapy of diabetes?
    Ceriello A
    Diabet Med; 2005 Nov; 22(11):1463-4. PubMed ID: 16241907
    [No Abstract]   [Full Text] [Related]  

  • 14. US regulators relax restrictions on rosiglitazone.
    McCarthy M
    BMJ; 2013 Nov; 347():f7144. PubMed ID: 24286989
    [No Abstract]   [Full Text] [Related]  

  • 15. PROactive study.
    Yudkin JS; Freemantle N
    Lancet; 2006 Jan; 367(9504):24-5; author reply 26-7. PubMed ID: 16399143
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies of diabetes, thiazolidinediones, and coronary heart disease.
    Walker AM; McAfee AT; Koro C
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1313-4; author reply 1314-6. PubMed ID: 18041104
    [No Abstract]   [Full Text] [Related]  

  • 17. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus.
    Sauer WH; Cappola AR; Berlin JA; Kimmel SE
    Am J Cardiol; 2006 Mar; 97(5):651-4. PubMed ID: 16490431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis.
    Nishio K; Kobayashi Y
    Cardiovasc Revasc Med; 2010; 11(4):227-31. PubMed ID: 20934654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary: the PROactive study--the glass is half full.
    Fonseca V; Jawa A; Asnani S
    J Clin Endocrinol Metab; 2006 Jan; 91(1):25-7. PubMed ID: 16303829
    [No Abstract]   [Full Text] [Related]  

  • 20. Diabetes drug safety update: Avandia and your heart.
    Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.